Key result
Esdn gene deletion in mice enhanced insulin signaling in liver, muscle, and adipose tissue, resulting in improved insulin sensitivity and glucose homeostasis in vivo.
Why the study?
Does Esdn gene deletion improve insulin signaling and sensitivity in mice and vascular smooth muscle cells?
Does Esdn gene deletion improve insulin signaling and sensitivity in mice and vascular smooth muscle cells?
ESDN acts as an inhibitor of insulin receptor signal transduction, and its deletion improves insulin sensitivity and glucose homeostasis, suggesting a novel therapeutic target for insulin resistance.
ESDN inhibition may be a novel target for insulin resistance; hypothesis-generating from animal data and requires human validation.
Insulin effects on cell metabolism, growth, and survival are mediated by its binding to, and activation of, insulin receptor. With increasing prevalence of insulin resistance and diabetes there is considerable interest in identifying novel regulators of insulin signal transduction. The transmembrane protein endothelial and smooth muscle cell-derived neuropilin-like protein (ESDN) is a novel regulator of vascular remodeling and angiogenesis. Here, we investigate a potential role of ESDN in insulin signaling, demonstrating that Esdn gene deletion promotes insulin-induced vascular smooth muscle cell proliferation and migration. This is associated with enhanced protein kinase B and mitogen-activated protein kinase activation as well as insulin receptor phosphorylation. Likewise, insulin signaling in the liver, muscle, and adipose tissue is enhanced in Esdn(-/-) mice, and these animals exhibit improved insulin sensitivity and glucose homeostasis in vivo. The effect of ESDN on insulin signaling is traced back to its interaction with insulin receptor, which alters the receptor interaction with regulatory adaptor protein-E3 ubiquitin ligase pairs, adaptor protein with pleckstrin homology and Src homology 2 domain-c-Cbl and growth factor receptor bound protein 10-neuronal precursor cell-expressed developmentally downregulated 4. In conclusion, our findings establish ESDN as an inhibitor of insulin receptor signal transduction through a novel regulatory mechanism. Loss of ESDN potentiates insulin's metabolic and mitotic effects and provides insights into a novel therapeutic avenue.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) studied Insulin resistance and diabetes. Esdn gene deletion vs. Wild-type (normal ESDN expression) was evaluated on Insulin signaling, sensitivity, and glucose homeostasis. Esdn gene deletion in mice enhanced insulin signaling in liver, muscle, and adipose tissue, resulting in improved insulin sensitivity and glucose homeostasis in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: